Chester County News and Community Website
NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More
WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial evaluating firmonertinib as a first-line treatment …
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded two new research grants to support studies on zipalertinib, a promising therapy for Non-Small …
NCCN Awards Grants to Advance Innovative Lung Cancer Research on Zipalertinib Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated …
FDA Grants Accelerated Approval for DATROWAY in Advanced EGFR-Mutated Lung Cancer Read More
HARRISBURG, PA — The American Lung Association in Pennsylvania is leading the charge against lung cancer this week, turning major landmarks turquoise as part of Turquoise Takeover and Lung Cancer …
Pennsylvania Goes Turquoise for Lung Cancer Awareness Read More WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth …
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025 Read More
HARRISBURG, PA — The Pennsylvania Department of Environmental Protection (DEP) recently announced the winners of the 2025 Pennsylvania Student Radon Poster Contest while continuing its educational campaign urging residents to …
Is Your Home Safe? Pennsylvania Urges Action Against Deadly Radon as Young Artists Lead the Fight Read More
HARRISBURG, PA — Nearly 40% of homes in Pennsylvania have elevated levels of radon, a colorless, odorless, and tasteless gas that is silently wreaking havoc across the state. According to the …
Radon Alert in Pennsylvania—Test Your Home Before It’s Too Late! Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More